• Alexion Pharmaceuticals Inc., of Cheshire, Conn., posted higher-than-expected Soliris (eculizumab) sales of $400.4 million for the third quarter, up 36 percent year over year. Analyst estimates had predicted sales of $395 million. The company attributed the growth to steady additions of new patients with paroxysmal nocturnal hemoglobinuria and increasing numbers of new patients with atypical hemolytic uremic syndrome beginning Soliris treatment in the U.S. and Europe.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter